Wei Chen

Dr. Wei Chen

Wenzhou Medical University, Wenzhou, Zhejiang, China
orcid
Wenzhou Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Wei ChenWei Chen
Wei Chen
YLyanz Li
yanz Li
CZChuting Zhang
Chuting Zhang
HZHang Zhou
Hang Zhou
JMJun Ma
Jun Ma
JZJianjian Zheng
Jianjian Zheng
Background: Hepatocellular carcinoma (HCC) remains a significant therapeutic challenge due to its complex molecular mechanisms and limited effective treatments. Although the Tibetan medicine Liuwei Muxiang Pill (LWMX) has shown efficacy in gastric and colorectal cancer, no study has yet demonstrated its potential anti-HCC activity. Objective: To evaluate the therapeutic effects of LWMX on HCC. Methods: Integrating network pharmacology, high-resolution mass spectrometry, machine learning, and molecular dynamics simulations, combined with in vitro experiments for mechanism validation. Results: The study identified (Checkpoint kinase 1) CHK1 as a key target of LWMX in HCC regulation and confirmed that quercetin can form a stable complex with CHK1. In vitro experiments demonstrated that LWMX and its active component quercetin significantly inhibit the proliferation and migration of HCC cells. Conclusions: The study establishes CHK1 as a key therapeutic target, confirming the potential of LWMX and its core component quercetin in the treatment of HCC.

3 January 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WGWei Gong
Wei Gong
Deep K. VaishnaniDeep K. Vaishnani
Deep K. Vaishnani
XJXuan-Chen Jin
Xuan-Chen Jin
JZJing Zeng
Jing Zeng
Wei ChenWei Chen
Wei Chen
JMJun Ma
Jun Ma
Objective: Rapid on-site evaluation (ROSE) of respiratory cytology specimens is a critical technique for accurate and timely diagnosis of lung cancer. However, in China, limited familiarity with the Diff-Quik staining method and a shortage of trained cytopathologists hamper utilization of ROSE. Therefore, developing an improved deep learning model to assist clinicians in promptly and accurately evaluating Diff-Quik stained cytology samples during ROSE has important clinical value. Methods: Retrospectively, 116 digital images of Diff-Quik stained cytology samples were obtained from whole slide scans. These included 6 diagnostic categories - carcinoid, normal cells, adenocarcinoma, squamous cell carcinoma, non-small cell carcinoma, and small cell carcinoma. All malignant diagnoses were confirmed by histopathology and immunohistochemistry. The test image set was presented to 3 cytopathologists from different hospitals with varying levels of experience, as well as an artificial intelligence system, as single-choice questions. Results: The diagnostic accuracy of the cytopathologists correlated with their years of practice and hospital setting. The AI model demonstrated proficiency comparable to the humans. Importantly, all combinations of AI assistance and human cytopathologist increased diagnostic efficiency to varying degrees. Conclusions: This deep learning model shows promising capability as an aid for on-site diagnosis of respiratory cytology samples. However, human expertise remains essential to the diagnostic process.

1 April 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JMJun Ma
Jun Ma
Wei ChenWei Chen
Wei Chen
Deep K. VaishnaniDeep K. Vaishnani
Deep K. Vaishnani
CWCongying Wang
Congying Wang
SXShuman Xue
Shuman Xue
FYFurong Ying
Furong Ying
Objective: To evaluate the therapeutic potential of the curcumin analog J7 in protecting the liver and regulating glucose and lipid metabolism in rats with type 2 diabetes. Methods: Bioinformatics methods were used to identify signaling pathways linked to diabetic liver disease. Diabetic rats were treated with curcumin, low-dose J7, or high-dose J7, and liver function and fibrosis were assessed through biochemical analyses, histopathology, immunohistochemistry, and ELISA. Results: J7 administration significantly improved lisver function, reduced fibrosis, and regulated metabolic profiles in diabetic rats. J7 downregulated TGF-β 1, NF-κB p65, and BAX, while upregulating BCL-2, showing superior effects to traditional curcumin in reducing TGF-β 1 and inhibiting α-SMA expression. Conclusion: J7 demonstrates potential as a therapeutic agent for managing liver complications in type 2 diabetes, effectively attenuating liver fibrosis and regulating metabolism through the modulation of key signaling pathways and proteins. Plain Language Summary: Diabetes is a common condition that can cause serious problems in the liver, such as damage and scarring (fibrosis). These problems are linked to how the body handles sugar and fat. Right now, there are not many effective treatments for diabetes-related liver issues. Our study looked at a new drug called J7, which is based on curcumin, a natural compound found in turmeric, to see if it could help protect the liver and improve sugar and fat metabolism. We used a rat model of type 2 diabetes to test J7. Rats were given either curcumin, a low dose of J7, or a high dose of J7. We then measured how well their livers were working and examined their liver tissue under a microscope. We also looked at the levels of specific molecules in the liver that are involved in inflammation, scarring, and cell survival. We found that J7 worked better than regular curcumin. It reduced liver damage, improved how the liver handled sugar and fat, and lessened scarring. J7 achieved this by affecting certain biological pathways, like the TGF-β/Smad pathway and NF-κB signaling, which are key players in liver damage and inflammation. These results suggest that J7 could be a promising new treatment for liver problems in people with diabetes. This study highlights the potential of improving natural compounds like curcumin to make them more effective as medicines. Further research is needed to explore how J7 might help people with diabetes and liver issues.

10 February 2026 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
YGYuxiang Gao
Yuxiang Gao
Wei ChenWei Chen
Wei Chen
Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
MYMurali M. Yallapu
Murali M. Yallapu
Miloš NikolićMiloš Nikolić
Miloš Nikolić
QXQiyu Xu
Qiyu Xu

7 July 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SHSi-Si Huang
Si-Si Huang
Wei ChenWei Chen
Wei Chen
DVDeep K Vaishnani
Deep K Vaishnani
LHLi-Juan Huang
Li-Juan Huang
JLJi-Zhen Li
Ji-Zhen Li
QXQipeng Xie
Qipeng Xie
BACKGROUND Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, primarily due to tumor heterogeneity and treatment resistance. The leucine-rich repeat-containing protein 19 (LRRC19) has been linked to immune regulation and tumor suppression, yet its specific role in CRC remains poorly understood. AIM To investigate the tumor-suppressive role of LRRC19 in CRC, focusing on cell cycle, immune microenvironment, and chemotherapy response. METHODS Bioinformatics analyses of Gene Expression Omnibus and The Cancer Genome Atlas databases identified differentially expressed genes in CRC. LRRC19 expression was validated in CRC tissues and cell lines by quantitative PCR, immunohistochemistry, and Western blotting. Functional assays, including proliferation, soft agar colony formation, flow cytometry, and xenograft models, assessed biological effects. Mechanistic studies with dual-luciferase reporter assays, molecular docking, and drug sensitivity testing explored LRRC19’s interaction with the cyclin-dependent kinase 6 (CDK6)/E2F1 axis and oxaliplatin (OXA) response. Single-cell sequencing and immune infiltration analyses assessed its impact on the immune microenvironment. RESULTS LRRC19 expression was significantly downregulated in CRC and associated with poor prognosis. Overexpression of LRRC19 inhibited CRC cell proliferation, induced G0/G1 phase arrest, and suppressed tumor growth in vivo . Mechanistically, LRRC19 suppressed CDK6 transcription by downregulating E2F1, leading to cell cycle arrest. Additionally, LRRC19 promoted immune cell infiltration, particularly B cells and CD4+ T cells, while decreasing immunosuppressive cells. LRRC19 also sensitized CRC cells to OXA, enhancing chemotherapy efficacy. CONCLUSION LRRC19 suppresses CRC by targeting the CDK6/E2F1 axis, modulating the immune microenvironment, and enhancing chemotherapy sensitivity, making it a promising therapeutic target for precision medicine in CRC.

27 December 2024 in Journal of Genetics
Verified
Journal Article
Closed access
PDF file
YMYi Ma
Yi Ma
YHYuli Hu
Yuli Hu
YLYi Lin
Yi Lin
CWCongying Wang
Congying Wang
YLYujie Lv
Yujie Lv
Wei ChenWei Chen
Wei Chen